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ABSTRACT 46 
Background  47 
Data on long-term outcomes in patients undergoing transcatheter aortic valve implantation (TAVI) is 48 
scarce. 49 
Methods  50 
We investigated long term outcomes of consecutive patients undergoing TAVI with balloon- and self-51 
expandable bioprostheses (Edwards SAPIEN (ESV), Edwards Lifesciences Inc., Irvine, CA, USA; 52 
Medtronic Corevalve system (MCS), Medtronic Inc., Minneapolis, MN, USA). 53 
Results 54 
Among 628 patients (mean age 82.4±5.8 years, 55% female), 489 (77.8%) underwent transfemoral 55 
TAVI. 309 (63.2%) patients received a MCS prosthesis, whereas 180 (36.8%) patients were treated 56 
with an ESV prosthesis. The median duration of follow-up amounted to 5.2 years (range 3.4–8.3 57 
years). All-cause mortality did not differ between the two groups (MCS 46.9%, ESV 53.4%, CI 95%: RR 58 
1.21 [0.93–1.57], P = 0.15), whereas cardiac mortality was higher in the ESV cohort after 5 years of 59 
follow-up (MCS 35.1%, ESV 45.4%, CI 95%: RR 1.37 [1.01–1.86], P = 0.04). Structural valve 60 
deterioration, which was on average diagnosed 41.9 months (range 18–60 months) after TAVI, 61 
occurred in 8 cases (1.6%), resulting in one repeat intervention. 62 
Conclusions 63 
While half of all patients died within 5 years after TAVI with no significant differences in all-cause 64 
mortality, structural valve deterioration was documented in b2% of cases.  65 
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INTRODUCTION 66 
Transcatheter aortic valve implantations (TAVI) are rapidly expanding towards the low risk spectrum 67 
of patients with severe aortic stenosis. Randomized controlled trials showed comparable safety and 68 
efficacy of both, self- and balloon-expandable prostheses, as compared to surgical aortic valve 69 
replacement [1–3]. Regarding the use of TAVI in younger patients, the question of long-term 70 
outcomes and in particular of valve durability becomes of major importance. However, there is a 71 
significant lack of data regarding these factors, which can also be seen as directories regarding the 72 
decision making in favor of TAVI or surgical aortic valve replacement (SAVR) in patients with a lower 73 
operative risk profile. The aim of the present analysis was to evaluate the long-term outcomes 74 
regarding the performance of the two most widely used TAVR systems: the balloon-expandable 75 
Edwards SAPIEN valve (ESV) (Edwards Lifescience Inc., Irvine, CA, USA) and the self-expandable 76 
Medtronic Corevalve system (MCS) (Medtronic Inc., Minneapolis, MN, USA) in patients undergoing 77 
TAVI for severe symptomatic aortic valve stenosis. 78 
 79 
METHODS 80 
Study population 81 
Between July 2007 and January 2013, all patients undergoing TAVI at the Swiss Cardiovascular 82 
Center of Bern University Hospital in Switzerland were consecutively recorded in a prospective 83 
registry held at the Clinical Trials Unit of the University of Bern in Switzerland. Inclusion criteria 84 
consisted of a) symptomatic, severe aortic stenosis (AS) with an echocardiographic mean gradient 85 
>40 mm Hg or a calculated aortic valve area <1 cm2 and b) age ≥ 80 years with a high operative risk 86 
score (logistic European System for Cardiac Operative Risk Evaluation (EuroSCORE) >15%). Patients 87 
<80 years of age were eligible if at least one of the following comorbid conditions were present: 88 
previous cardiac surgery, liver cirrhosis, chronic pulmonary disease (forced expiratory volume <1 l/s), 89 
severe pulmonary hypertension, porcelain aorta, history of mediastinal radiotherapy, severe 90 
connective tissue disease with contraindication for surgery, or frailty. Additionally, anatomical 91 
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prerequisites consisted of an aortic annulus diameter in the range of 18 to 27 mm and a vascular 92 
access site suitable for transfemoral TAVI. Exclusion criteria included degenerated aortic valve 93 
prostheses and severe aortic regurgitation in the absence of AS. An interdisciplinary team of cardiac 94 
surgeons and interventional cardiologists reviewed all cases and formed a consensus on treatment 95 
allocation (TAVI or SAVR). The registry as well as the study have been approved by the local cantonal 96 
ethics committee and comply with the Declaration of Helsinki. All patients enrolled in the database 97 
provided written informed consent. 98 
 99 
Definitions and procedures 100 
Patients undergoing TAVI underwent comprehensive multimodal assessment using transthoracic and 101 
transesophageal echocardiography, right and left heart catheterization, and contrast computed 102 
tomography. TAVI was performed according to standard protocols via transfemoral approach using 103 
both balloon-expandable ESV (Sapien THV and XT) and self-expandable MCS. Device selection was 104 
based on anatomical and technical characteristics as described previously [4]. Pre- and postdilatation 105 
were performed according to the operators' discretion. Postinterventional antithrombotic and 106 
antiplatelet treatment was prescribed according to the discretion of the operator. For definitions of 107 
outcome variables see Supplemental File 1. Procedural success was defined as device success in the 108 
absence of major adverse cardiovascular and cerebral events during the first 48 h after device 109 
implantation. Device success was defined according to VARC-2 criteria. Bioprosthetic valve 110 
dysfunction, including valve deterioration, thrombosis, and endocarditis, was defined according to 111 
the consensus statement from the European Association of Percutaneous Cardiovascular 112 
Interventions (EAPCI). 113 
 114 
Data collection 115 
Demographic characteristics, imaging parameters, hemodynamic measurements, and procedural 116 
variables were prospectively recorded in a web-based database. All patients underwent sweep 117 
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follow-up between April and November 2017 which was performed by means of standardized 118 
telephone interviews. In addition, medical records, discharge summaries, and documentation of 119 
hospitalization were systematically collected from general practitioners, referring cardiologists as 120 
well as referring hospitals for verification of clinical endpoints. For a validated calcification score 121 
analysis [5], measurements were done at theHU-850 threshold in Contrast CT images. All endpoints 122 
were defined according to the updated version of the Valve Academic Research Consortium (VARC-123 
2) definitions [6], and adjudicated by a clinical event committee, which consists of interventional 124 
cardiologists and cardiac surgeons from different institutions. 125 
 126 
Statistical analysis 127 
Continuous data are reported as mean ± standard deviation (SD) if their distribution is approximately 128 
normal and as median/range otherwise. The means were compared using analysis of variance and 129 
differences in medians were analysed with Mann-Whitney test. Categorical variables are expressed 130 
as number of patients (% of patients). Survival was estimated using the Kaplan-Meier method and 131 
differences in estimates were compared by means of the log-rank test. The at-risk time span was 132 
derived from the date of intervention and the last available data of the patient, determined either 133 
by the last follow-up, the time of death, or information coming from referring hospitals and/or 134 
practitioners. Survival estimates were calculated using univariate and multivariate Cox proportional 135 
hazard models including landmark analyses. Reported are crude hazard ratios (HR; with 95% 136 
confidence intervals) with p-values from Wald chi-square tests, or continuity correct risk ratios with 137 
p-values from Fisher's exact tests. P-values <0.05were considered statistically significant. For 138 
adjusted analyses, baseline and pre-TAVI characteristics were included that showed a difference 139 
between the two groups with a p-value b 0.1 (TAVI device, sex, body mass index, previous CABG, 140 
previous stroke or TIA, prior permanent pacemaker, EuroScore, aortic valve area, LV ejection 141 
fraction, and calcification score). All analyses were performed with Stata version 14 (StataCorp, 142 
College Station, TX, USA). 143 
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 146 
RESULTS 147 
Among 628 patients (mean age 82.4 ± 5.8 years, 54.6% female), 489 patients (77.8%) underwent 148 
transfemoral TAVI for native aortic valve stenosis. Patients undergoing transapical (N = 124, 19.7%) 149 
or trans-subclavian (N = 9, 1.4%) TAVI, as well as patients with a transcatheter-valve-in-surgical-valve 150 
procedure (N = 6, 1%) were excluded from the present analysis. 309 (63.2%) patients were treated 151 
with a MCS whereas 180 (36.8%) patients received an ESV (ESV THV in 27 (5.5%) cases, ESV XT in 153 152 
(31.3%) cases). Baseline clinical characteristics at the time of intervention are summarized in Table 1. 153 
Both, patients in the MCS and the ESV cohort, were comparable with respect to cardiovascular risk 154 
factors, clinical features, symptom status, and preinterventional antithrombotic therapy. While more 155 
female patients underwent implantation of a MCS (MCS 46.3% vs. ESV 35%, P = 0.0148), patients in 156 
the ESV cohort had more frequently experienced a previous stroke or transient ischemic attack (TIA) 157 
as compared with MCS patients (ESV 10.8% vs. MCS 4.8%, P = 0.0136). Echocardiographic imaging 158 
characteristics are outlined in Table 2. No significant preinterventional differences between the two 159 
treatment arms could be noted except a higher left ventricular ejection fraction (LVEF) within the 160 
ESV group (ESV 56.6% vs. MCS 51.8% vs., P=0.0004). Furthermore, measurements from left/right 161 
heart catherization were comparable between the two groups (Supplemental Table 1). 162 
 163 
Procedural outcomes 164 
Procedural data are depicted in Supplemental Table 2. Procedure time did not significantly differ 165 
between MCS and ESV and took on average 67.5 min (P = 0.52). Implantation of a MCS valve 166 
required more contrast dye (MCS 266.7 ± 102.7 ml, ESV 225.7 ± 96 ml, P ≤0.001) and was less 167 
frequently performed with a balloon predilatation as compared with the implantation of an ESV 168 
(MCS 92.6% vs. ESV 99.4%, P=0.0007). After intervention, patients treated with an ESV had a higher 169 
Published in final form edited form as: Int J Cardiol. 2019 Sep 1;290:45-51. doi: 10.1016/j.ijcard.2019.03.050 
mean aortic valve gradient (MCS 7.2 ± 3.7 mm Hg, ESV 8.5 ± 4.0 mm Hg, P = 0.0003) whereas the 170 
need for permanent pacemaker implantation was higher in the MCS cohort (MCS 29.8% vs. ESV 171 
14.4%, P = 0.0001). Postprocedural moderate to severe aortic regurgitation occurred more 172 
frequently among patients treated with a MCS valve (MCS 19.1% vs. ESV 4.5%, P ≤0.0001). The mean 173 
hospital duration was 9.1 (7.2 ± 12.3) days with a longer duration for patients treated with a MCS 174 
prosthesis (MCS 9.1 (8.4 ± 12.4) days, ESV 8.3 (7.3 ± 11.1) days, P = 0.02). In 11 cases, all of which 175 
occurred within the MCS cohort (3.6%, P = 0.01), the implantation of more than one valve in series 176 
was required. 177 
 178 
Clinical outcomes 179 
Comparisons of clinical outcomes are descriptive. The median duration of follow-up amounted to 5.2 180 
years (range 3.4–8.3 years). None of the patients was lost to follow-up. Event rates with crude 181 
hazard ratios for all major clinical endpoints according to VARC through 30 days, 3 years, and 5 years 182 
are provided in Supplemental Table 3. All-cause mortality throughout 5 years of follow-up did not 183 
differ between the two groups (MCS 46.9%, ESV 53.4%, RR 1.21 [0.93–1.57], P = 0.15) whereas 184 
cardiac mortality was higher in the ESV cohort, taking effect after 3 years (30 days: MCS 3.9%, ESV 185 
5.6%, RR 1.59 [0.67–3.75], P = 0.29; 3 years: MCS 21.6%, ESV 24.5%, RR 1.18 [0.8–1.75], P = 0.4; 5 186 
years: MCS 35.1%, ESV 45.4%, RR 1.37 [1.01–1.86], P = 0.04). Fig. 1 shows cumulative event rates for 187 
all-cause mortality, cardiac mortality, and major stroke throughout 5 years stratified for MCS and 188 
ESV and including landmark analyses (0 to 30 days, 31 days to 5 years) with the aforementioned 189 
described significant difference in long-term cardiac mortality (P = 0.04) between the two groups. 190 
The landmark analyses as such did not show any further significant differences between the two 191 
valve types (Supplemental Table 4). Adjusted univariable analyses showed an association between 192 
all-cause mortality and female gender (HR 0.73, 95% CI 0.57–0.95; P = 0.0183), previous CABG (HR 193 
1.60, 95% CI 1.03–2.49; P = 0.0355), logistic EuroScore (HR 1.02, 95% CI 1.01–1.03; P b 0.001), and 194 
LVEF (HR 0.99, 95% CI 0.98–1.00; P=0.0052), between cardiac mortality and the implantation of an 195 
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ESV (HR 1.37, 95% CI 1.01–1.86; P=0.0409), logistic EuroScore (HR 1.03, 95% CI 1.02–1.04; P <0.001), 196 
and LVEF (HR 0.98, 95% CI 0.97–0.99; P = 0.0006), whereas major stroke was associated with 197 
previously occurred strokes or transitoric ischemic attacks (HR 3.27, 95% CI 1.23–8.72; P = 0.0177). 198 
Univariable and multivariable adjusted analyses are illustrated in Supplemental Tables 5 and 6. 199 
 200 
Echocardiographic follow-up and time-related valve safety 201 
Post-procedural echocardiographic data relate to the last available transthoracic echocardiographic 202 
follow-up performed at the university center or at an outpatient cardiology center. After three years, 203 
echocardiographic data amounted to 72% of cases; after five years echocardiographic follow-up data 204 
was available in 65% of cases. While mean and peak aortic valve (AV) gradients as well as LVEF were 205 
higher in the ESV cohort (mean AV gradient: MCS 8.85 ± 4.75 mm Hg; ESV 10.25 ± 4.52 mm Hg, P = 206 
0.0033; peak AV gradient: MCS 16.23 ± 9.4 mm Hg; ESV 18.59 ± 8.69 mm Hg, P = 0.0277; LVEF: MCS 207 
55.55 ± 12.43 mm Hg; ESV 57.83 ± 10.94 mm Hg, P = 0.0543), severe pulmonary hypertension (MCS 208 
40.4% vs. ESV 26.9%, P=0.0335) and moderate or severe aortic regurgitation (MCS 19% vs. ESV 9%, P 209 
= 0.0055) were more frequently observed in patients treated with a MCS valve. Regarding relevant 210 
aortic regurgitation, no significant change could be seen over time after TAVI in both, MCS and ESV 211 
treated patients (MCS: P = 0.1384, ESV: P=0.0621). The degree and changes in aortic regurgitation 212 
before and after treatment have been depicted in Supplemental Figs. 1 and 2. In total, 8 cases (1.6%) 213 
of structural valve deterioration (SVD) (3 MCS (1%), 5 ESV (2.8%)) occurred during the follow-up 214 
time. On average, prosthetic SVD was diagnosed 41.9 months (range 18–60 months) after TAVI. 215 
Moderate SVD occurred in 7 cases (ESV: 4 (2.2%), MCS: 3 (1%)), whereas severe SVD was only found 216 
in one patient (ESV, 0.6%). Details are shown in Supplemental Tables 7 and 8 as well as in Fig. 2. A 217 
repeat procedure due to SVD was performed in only one case 4.6 years after implantation of an ESV 218 
XT 26 mm (mean AV gradient 64 mm Hg, aortic valve area (AVA) 0.6 cm2) with a successful valve-in-219 
valve procedure using a MCS valve. All other cases of SVD were treated conservatively. In addition to 220 
the SVD case, valve-related repeat interventions were performed in another four patients (0.1%). In 221 
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two patients, who were primarily treated with a MCS-valve, a balloon dilatation of the transcatheter 222 
valve was performed due to relevant paravalvular regurgitation 13 days and 14 days after the index 223 
procedure. One patient with a MCS valve developed severe paravalvular aortic regurgitation after 224 
1.3 years and was treated with another MCS prosthesis. Another patient was diagnosed with an 225 
aorto-right ventricular fistula 1.3 months after implantation of an ESV prosthesis resulting in a fistula 226 
occlusion with a coil [7]. In total, two cases of prosthetic valve endocarditis were diagnosed. One 227 
with an ESV XT 26 mm valve 2.6 years after implantation and the other one with an ESV XT 23 mm 228 
4.8 years after implantation. No case of manifest prosthetic valve thrombosis occurred during the 229 
follow-up. 230 
 231 
DISCUSSION 232 
We present long-term clinical outcomes of patients with a symptomatic severe AS treated with 233 
transfemoral TAVI using either a balloon-expandable (ESV) or a self-expandable (MCS) prosthesis. 234 
The key findings can be summarized as follows: (1) >50% of patients died within 5 years after TAVI; 235 
there were no differences in all-cause mortality and major stroke between patients treated with 236 
either a balloon-expandable ESV or a self-expandable MCS prosthesis; (2) Structural valve 237 
deterioration occurred in <2% of survivors and was diagnosed on average 3.5 years after the index-238 
procedure; (3) Repeat interventions for prosthetic heart valve related problems were rare.  239 
Our results of a high efficacy of both, the balloon-expandable ESV and the self-expandable MCS 240 
valve, can be confirmed through various studies [8–10]. However, valve-specific drawbacks have 241 
been previously described as well. In patients treated with a MCS prosthesis, we observed a higher 242 
need for permanent pacemaker implantation (29.8% vs. 14.4% at 30 days, P = 0.0001), which was 243 
consistent with previous reports [11–14]. This fact is most likely due to the deeper extension of the 244 
valve into the left ventricular outflow tract in addition to the self-expanding nature of its frame 245 
applying constant pressure on the atrioventricular conductance system. Regarding rates of 246 
atrioventricular conduction disturbance and potential impact on long-term mortality, conflicting 247 
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evidence exists. While data from our cohort suggested that preprocedural pacemaker implantation 248 
does not adversely affect clinical outcomes, data of the PARTNER study showed that the presence of 249 
a pacemaker (pre- or periprocedural) was independently associated with increased 1-yearmortality 250 
[15,16]. However, further technical developments, such as adjustments of the valve frame and 251 
additional modifications of the catheter, which allows a more accurate positioning of the valve, may 252 
further reduce the likelihood of a pacemaker dependency [17,18]. 253 
In addition, patients treated with MCS more commonly had paravalvular regurgitation as compared 254 
to patients treated with ESV (19.1% vs. 4.5%, P ≤0.001), which has previously been associated with 255 
worse long-term clinical outcomes [19]. Our results are in line with reported rates of relevant AR 256 
after TAVI with early generation devices ranging from 15% to 20% [20–24]. Most of the cases of 257 
no/mild aortic regurgitation at baseline that worsened were worsening from mild to moderate aortic 258 
regurgitation. Improved valve positioning and stabilisation resulting in predictable implantation 259 
depth in combination with refinements of the prosthesis with skirts, cuffs, and seals, have 260 
significantly reduced the rate of paravalvular regurgitation [25,26]. Despite the higher rates of 261 
moderate to severe paravalvular regurgitation, valve in series procedures, and permanent 262 
pacemaker implantation in the MCS group, there was no excess mortality in this cohort, even though 263 
all of these complications have been associated with worse outcomes as described above. This 264 
paradoxon may be partially explained by the moderate sample size of this study as well as by 265 
“background” events of death occurring in octogenerians as already hypothesized by the one year 266 
results of the CHOICE trial [27]. 267 
The observed all-cause mortality rate of 30.8% for MCS and 32.9% of ESV prosthesis in our cohort as 268 
well as the cardiac mortality rate of 21.6% for the MCS and 24.5% for the ESV cohort at 3-year 269 
follow-up is within the range of previous reports, albeit at the lower end [28–31]. Outcome data 270 
beyond 3 years in terms of comparison of the two most widely used TAVI systems is scarce. Bouleti 271 
et al. showed a 5-year event-free survival rate of 28% ± 4%, however, the study cohort was small (N 272 
= 123) and in >90% of patients, an ESV prosthesis was used [32]. In the study of Tarantini and 273 
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colleagues, 171 patients were treated (MCS: N = 87, ESV: N = 84) with an overall survival rate of 274 
44.9% at 5 years without a difference between valve types [33]. Data of the UK TAVI Registry with an 275 
almost balanced implantation rate between MSC and ESV prostheses, presented a 5 year all-cause 276 
mortality rate of 53.1% being in line with our findings (MCS 46.9%, ESV 53.4%). Valve type 277 
differences at 5 years as well as data on cardiac mortality were not presented. Our results showed a 278 
statistically higher cardiac mortality in the ESV group (MCS 35.1% vs. ESV 45%, P=0.04) taking effect 279 
after 3 years. Crude cardiac mortality rates of patients treated with an ESV prosthesis were lower as 280 
compared with the 5-year results from the PARTNER trial (45.4% vs. 57.5%) [30]. Of note, no 281 
relevant difference in calcification volume could be found within the two cohorts. Due to the 282 
observational nature of this single center study these results have to be interpreted with caution. 283 
Notwithstanding, and with the knowledge that a lot of morbidities unrelated to cardiovascular 284 
disease heavily contribute to death in the long-term, this effect requires further scrutiny and needs 285 
to be considered for further analyses comparing the two valve systems. The incidence of adverse 286 
events including stroke at 3 and at 5 years were comparable to other reports and showed no 287 
differences between the valve types. 288 
The low incidence of time-related valve safety events according to VARC is reassuring and 289 
comparable to other long-term TAVI studies [29,34,35]. Structural valve deterioration occurred in 8 290 
patients (1.6%) in both, patients treated with an ESV or MCS-valve. Referring to the consensus 291 
statement from the European Association of Percutaneous Cardiovascular Interventions [36], 292 
moderate SVD occurred more frequently as compared with severe SVD, underlined by data from the 293 
NOTION trial [37]. While reported rates of structural valve deterioration in surgically implanted 294 
aortic valve prostheses requiring reoperation range from 6–47% by 12 to 29 years after 295 
implantation, reports of transcatheter valve durability are needed to safely expand TAVR to the low 296 
risk spectrum of younger patients [38–42]. The observation of subclinical leaflet thrombosis (SLT) 297 
has recently raised concerns and may affect long-term clinical outcomes, in particular rates of 298 
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cerebrovascular events [41,42]. Further research is crucial in order to evaluate if actual rates of 299 
bioprosthetic valve dysfunction also relate to newer generation valves. 300 
The present analysis has to be interpreted against the background of several limitations. First, the 301 
number of patients included into the analysis was modest. Conversely, no patient was lost to clinical 302 
follow-up and reports on long-term outcome of patients undergoing TAVI are scarce. Second, data 303 
was acquired at a single center, thus not being generalizable to institutions with different referral 304 
patterns. Third, allocation to treatment with MCV and ESV was non-randomized; differences in 305 
clinical outcomes are therefore open to bias. Fourth, current data on long-term follow-up includes 306 
treatment with older generation valves resulting in a possible impact on generalizability. 307 
Furthermore, the assessment of long-term structural valve deterioration might be limited in high-risk 308 
populations with rather high mortality rates in the early TAVI era. Additionally, the lack of uniformity 309 
of echocardiography and the low follow-up data of echocardiography over time might have 310 
introduced a bias in addition to a possible bias of underestimation of valve thrombosis in the 311 
absence of routine multisliced computed tomography in SVD patients. However, the analyses 312 
represent treatment decisions and outcomes of consecutive patients as encountered in routine 313 
clinical practice. 314 
 315 
CONCLUSION 316 
More than 50% of patients undergoing TAVI died within 5 years of the procedure with no significant 317 
differences in all-cause mortality between MCS and ESV. Structural valve deterioration was 318 
documented in <2% of patients.  319 
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TABLES 441 
Table 1: Baseline clinical characteristics. 442 
Depicted are means ± SD with p-values from t-tests or counts (%) with p-values from Fisher's tests 443 
(two categories) or chi-square tests (more than two categories). BMI = Body mass index; CABG= 444 
Coronary artery bypass grafting; GFR = Glomerular Filtration Rate; MI=Myocardial infarction; 445 
IQR=Interquartile range; NYHA=New York Heart Association; PCI = Percutaneous coronary 446 
intervention; TIA = Transient ischemic attack; STS = Society of Thoracic Surgeons. 447 
  448 
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Table 2: Echocardiographic imaging characteristics. 449 
Pre- and post TAVI assessments via transthoracic echocardiography. Depicted are means ± SD with 450 
p-values from t-tests or counts (%) with p-values from Fisher's tests (two categories) or chi-square 451 
tests (more than two categories). LV = Left ventricle; TAVI= Transcatheter aortic valve implantation. 452 
 453 
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FIGURES 455 
Figure 1: (A) Cumulative incidence including landmark analysis of all-cause mortality according to 456 
transcatheter aortic valve type up to 5 years of follow-up. (B) Cumulative incidence including 457 
landmark analysis of cardiac mortality according to transcatheter aortic valve type up to 5 years of 458 
follow-up. (C) Cumulative incidence including landmark analysis of major stroke according to 459 
transcatheter aortic valve type up to 5 years of follow-up. 460 
Medtronic CoreValve (blue line), Edwards Sapien (red line). (For interpretation of the references to 461 
colour in this figure legend, the reader is referred to the web version of this article.) 462 
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Figure 2: Cumulative incidence of structural valve deterioration up to 5 years of follow-up. 464 
Medtronic CoreValve (blue line), Edwards Sapien (red line). (For interpretation of the references to 465 
colour in this figure legend, the reader is referred to the web version of this article.) 466 
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